FindTrial
Sign In

A Phase I Clinical Study of the Safety, Tolerability and Pharmacokinetics of HX-1171 in Healthy Male Subjects.

A Phase I Clinical Study, Randomized, Single-blind,Placebo-controlled, Multiple Doses, Dose Escalation Study fo the Safety, Tolerability and Pharmacokinetics of HX-1171 in Healthy Male Subjects.

Status
TEMPORARILY_NOT_AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT01889745
Acronym
HX-1171
Enrollment
Unknown
Registered
2013-06-28
Start date
Unknown
Completion date
Unknown
Last updated
2013-06-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

This study is designed to multiple dose and dose escalation study

Detailed description

A Phase I Clinical Study, Randomized, Single-blind, Placebo-controlled, Single Dose Escalation Study of the Safety, Tolerabiluty, and Pharmacokinetics of HX-1171 in Healthy Male Subjects

Interventions

DRUGHX-1171

Anti-oxidatant, Anti-inflamation

Sponsors

Biotoxtech Co., Ltd
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
MALE
Age
20 Years to 40 Years

Inclusion criteria

* Adult males aged 20 to 40 years at screening. * Be able to comply with the requirement of the study. Subject must provide written informed consent prior to study participation.

Exclusion criteria

* History or presence of liver, kidney, or nervous system disease, respiratory disorders, endocrinological disorders, hemato-oncologic, cardiovascular or psychiatric or gastrointestinal disorders. * History of known hypersensitivity to drugs including HX-1171.

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026